Full-Time

Principal Scientist

Immuno-Oncology Discovery

Confirmed live in the last 24 hours

Legend Biotech

Legend Biotech

1,001-5,000 employees

Develops and commercializes cell therapies

Biotechnology
Healthcare

Expert

Philadelphia, PA, USA

Category
Computational Biology
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD degree in biological sciences (Immunology, Immuno-Oncology, cancer biology) or related field is required.
  • Senior Scientist- PhD + 3 years of industry experience.
  • Principal Scientist- PhD, 5 years of postgraduate experience with a minimum of 4 years of Industry experience.
  • Previous work experience in target discovery, validation and IND filing in Cell therapy space is strongly preferred.
  • Relevance experience of utilizing αβT cell biology is required. Additional experience of using NK cell, γδT cell is strongly preferred.
  • Proficiency in conventional immunological techniques such as primary T cell isolation, gene editing/transduction, expansion, ELISA, cell sorting and flow cytometry is required.
  • Experience in CAR-T animal models, in vivo study design and execution is required.
  • In depth knowledge in topics such as human tumor microenvironment (TME), tumor-infiltrating-lymphocytes (TIL), tertiary lymphoid structures (TLS), Immune Checkpoint Blockade (ICB) is preferred. Hands-on experience with translational biomarker studies is preferred.
  • Innovation in cell therapy space is preferred as evidenced by publications and patents.
  • Language: English
Responsibilities
  • Design and execute CAR-T cell functional assays.
  • Design and execute in vivo studies with relevant human and murine tumor models.
  • Design and develop novel armor strategy.
  • Analyze and interpret data, troubleshooting, present to and engage internal stakeholders and cross-functional teams.
  • Stay abreast of the latest advancement of cell therapy in solid tumor. Demonstrate deep insight in selected disease area.

Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.

Company Stage

IPO

Total Funding

$146.4M

Headquarters

Franklin Township, New Jersey

Founded

2014

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-1%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Recent FDA and European approvals for CARVYKTI® expand its market reach in multiple myeloma.
  • New R&D facility in Philadelphia boosts innovation in next-generation cell therapies.
  • Alan Bash's appointment could accelerate CARVYKTI®'s growth and market penetration.

What critics are saying

  • Increased competition from Amgen's Imdelltra may impact CAR-T therapy focus.
  • Collaboration with Multiply Labs may face technological challenges, delaying production timelines.
  • Financial strain from new R&D facility could affect operational focus if advancements lag.

What makes Legend Biotech unique

  • Legend Biotech focuses on novel cell therapies for oncology, including CAR-T and NK cells.
  • The company is technology agnostic, exploring multiple platforms for effective cancer treatments.
  • Legend Biotech's CARVYKTI® is the first BCMA-targeted CAR-T therapy approved for second-line use.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Sick Leave

Paid Holidays

Remote Work Options